Due to various study designs with variable objectives and believability, evidence on preventing Alzheimer's disease (AD) is difficult to understand. Over the last few decades, there have been significant global efforts to update and upgrade the knowledge on how to prevent Alzheimer's disease (AD), which accounts for roughly two-thirds of all dementia cases and affects up to 20% of people over the age of 80. Nonetheless, inconsistency among conclusions and varying levels of credibility resulting from the large variety of study methods are major concerns in the discipline. Prevention programming that is evidence-based (EB) comprises of interventions and policies that have been proved to be successful in preventing the initiation and continuation of substance use and other problem behaviors through rigorous evaluations.
- Pathogenesis and Clinical Features in AD
- Pharmacological Treatment
Jacqueline Tuppen
Cogs Club, United Kingdom
Kaoru Sakatani
The University of Tokyo, Japan
Marco Orsini
Rio De Janeiro State University, BrazilSubmit your abstract Today
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Him, that person and me
Simon C Barton, Stroke Survivor, United States
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States